Pfizer (PFE) Subsequent Tender Offer for Icagen (ICGN) Expires
Get Alerts PFE Hot Sheet
Price: $27.75 -0.11%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 6.1%
EPS Growth %: -55.3%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 6.1%
EPS Growth %: -55.3%
Join SI Premium – FREE
Pfizer Inc. (NYSE: PFE) and Icagen, Inc. (Nasdaq: ICGN) announced today the expiration of the subsequent offering period of the cash tender offer by Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp., for all of the outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller in cash, without interest thereon, less any applicable withholding and transfer taxes.
The subsequent offering period expired at 6:00 p.m., New York City time, on Monday, September 19, 2011.
The subsequent offering period expired at 6:00 p.m., New York City time, on Monday, September 19, 2011.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rexford Industrial Realty (REXR) Acquires Blackstone (BX) Industrial Assets in $1B Deal
- Southwest Airlines (LUV) Acquires Saffire Renewables And Strengthens Focus On Sustainability
- Myomo (MYO) Appoints Heather Getz to its Board
Create E-mail Alert Related Categories
Corporate News, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!